All XRAYs

Study : Managing the side effects of advanced endometrial cancer treatment

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with advanced endometrial cancer

Immunotherapy plus targeted therapy is a treatment option for advanced endometrial cancer that has progressed after prior treatment. People who start the two-drug combination are more likely to have a positive experience if they learn about the possible side effects and when they might occur. The most common side effects and how to manage them are discussed in this review. (Posted 9/25/24)

Study : Combining two anti-HER2 drugs improves outcomes more effectively than one

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with Her2-positive metastatic breast cancer

Combining two anti-HER2 drugs increased the time until cancer returned for people with locally advanced or metastatic HER2-positive breast cancer compared to people who received just one anti-HER2 drug. People whose breast cancer had metastasized to the brain also benefitted from the two combined drugs. (Posted 9/17/24)

Update : News from the FDA: First-line treatment and biosimilars for prostate cancer

Relevance: Medium

Research Timeline: Post Approval

Most relevant for: People with prostate cancer

The FDA recently approved a first-line treatment for non-metastatic, castration-sensitive prostate cancer. Approval was also given to two new drugs known as biosimilars that can be used in place of two already approved biologics to prevent bone weakening, pain or fractures that may occur from certain hormone therapies or from cancer that has spread to the bone. (Posted 9/10/24)

Study : Colorectal cancer in people with Lynch syndrome can include types of cancer found more typically in people without Lynch syndrome

Relevance: Medium-High

Strength of Science: Medium-High

Most relevant for: People with Lynch syndrome and people with colorectal cancer who may have Lynch syndrome

When people with Lynch syndrome (LS) develop cancer, their tumors typically have a related set of features or biomarkers known as deficient mismatch repair (dMMR) and high microsatellite instability (MSI-High). However, occasionally people with Lynch syndrome have cancers that are proficient in mismatch repair (pMMR or MMR-P) and have microsatellite stability (MSS or MSI-Low) –more like the colorectal cancers found in people without Lynch syndrome. This study shows that 10 percent of people with Lynch syndrome may have these types of cancers. This can change treatment recommendations. (Posted 9/5/24)

Update : News from the FDA: Updates on breast cancer treatment

Relevance: Medium

Research Timeline: Post Approval

Most relevant for: People with BioZorb markers in breast tissue. People who will have a lumpectomy. People interested in cancer-related podcasts.

The FDA updates the risks of using BioZorb Markers, approves a new imaging drug and shares the Oncology Podcast Series. (Posted 8/16/24)

Topic : Acupressure for cancer symptom relief

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People diagnosed with cancer

Acupressure is a safe treatment that can be used to relieve some symptoms of cancer and side effects of treatment. Light pressure applied to key points on the body may help with fatigue, sleep, nausea and possibly other symptoms as well. (Posted 8/1/24)

Este artículo está disponible en español.

Study : Skin cancer among women with an inherited BRCA mutation

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Human Research

Most relevant for: People with an inherited BRCA mutation

Women with an inherited BRCA1 and BRCA2 mutation have an increased risk of various cancers. Study results suggest that although the risk of non-melanoma skin cancer in these women is similar to the risk of the general population, the risk of melanoma skin cancer is slightly increased. (Posted 7/25/24)

Este artículo está disponible en español.

Topic : The drug Enhertu is FDA-approved for any advanced or metastatic HER2-positive tumors

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

Most relevant for: People with advanced HER2-positive cancer

The FDA granted accelerated approval of Enhertu for people with any HER2-positive tumor that is metastatic or cannot be surgically removed. Eligible patients must have had previous treatment such as chemotherapy or hormone therapy. (Posted 7/19/24)

Este artículo está disponible en español.

Topic : Experts call for early palliative care for cancer patients

Relevance: Medium-High

View Related Clinical Trials

Most relevant for: Cancer patients

People with cancer need support and care not only at the end of life but from the time of diagnosis. At the 2024 American Society of Clinical Oncology (ASCO) annual meeting, the organization’s president urged cancer healthcare professionals to make palliative care central to cancer treatment. (Posted 7/17/24)

Este artículo está disponible en español.

Study : Yearly breast MRI screening improves outcomes for women with inherited BRCA mutations

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with a BRCA1 or BRCA2 mutation who are considering breast MRI screening

An international research study of yearly breast MRI screening among women with BRCA1 and BRCA2 gene mutations found that BRCA1 carriers who had MRI screenings were less likely to die of breast cancer than those who did not. Additional studies with more BRCA2 mutation carriers are needed to determine if yearly breast MRIs reduce deaths from breast cancer in this group. (Posted 6/24/24)

Este artículo está disponible en español.